Clinical trial
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor…
NCT04218266 · Bayer, Industry · Completed
Key facts
| NCT number | NCT04218266 |
|---|---|
| Title | Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications. |
| Official title | Multicenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study to Compare the Safety of the Oral FXIa Inhibitor BAY2433334 to Apixaban in Patients With Atrial Fibrillation |
| Acronym | PACIFIC-AF |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation (AF) |
| Intervention type | Drug, Other |
| Interventions | BAY2433334, Apixaban, BAY2433334 matching placebo, Apixaban matching placebo |
| Enrollment | 755 |
| Start date | Jan 30, 2020 |
| Primary completion | Oct 8, 2021 |
| Completion | Oct 8, 2021 |
| First posted | Jan 6, 2020 |
| Last update posted | Oct 27, 2022 |
| Countries | Austria, Belgium, Canada, Czechia, France, Hungary, Italy, Japan, Latvia, Netherlands, Spain, Sweden and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: